Elite Pharmaceuticals expands abuse deterrent technology
Edison Pharma announces EPI743 phase 2B3 Leigh Syndrome clinical trial with Dainippon Sumitomo
Bacterin International Holdings has secured $4 million in financing from investment firm OrbiMed
Visit our sites for b2b sales and banking employees:
cafeb2bsales.com
cafebanking.com
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Cordis | 1 | 14 | 1300 % |
| Alexion | 4 | 25 | 525 % |
| La Jolla Pharmaceutical | 1 | 6 | 500 % |
| Ellipse Technologies | 1 | 5 | 400 % |
| Daiichi Sankyo | 2 | 8 | 300 % |
| Emergent BioSolutions | 1 | 4 | 300 % |
| Braintree Labs | 1 | 4 | 300 % |
| Galena Biopharma | 1 | 4 | 300 % |
| Akamai | 3 | 10 | 233 % |
| Astellas | 1 | 3 | 200 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Cellular Dynamics | 4 | 44 | 1000 % |
| Capsule Technologies | 2 | 20 | 900 % |
| SIGA technologies | 3 | 29 | 867 % |
| Codexis | 2 | 15 | 650 % |
| La Jolla Pharmaceutical | 15 | 99 | 560 % |
| PharmAthene | 3 | 19 | 533 % |
| Theratechnologies | 1 | 6 | 500 % |
| Keryx | 9 | 54 | 500 % |
| Neuralstem | 9 | 50 | 456 % |
| Apricus Biosciences | 7 | 36 | 414 % |